Combination Weight Loss (CagriSema) Extensive Research The Phase 3 REDEFINE 1 trial demonstrated that CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) produced mean weight loss of 20.4% at 68 weeks in 3,417 adults with obesity or overweight without diabetes, compared to 14.9% with semaglutide alone, 11.5% with cagrilintide alone, and 3.0% with placebo
Read our guide on exercise recommendations when using Mounjaro for more support
consistent absorption and easy to self-administer Thigh (upper, outer) good for self-injection
Golper TA, Wolfson M, Ahmad S, Hirschberg R, Kurtin P, Katz LA, Nicora R, Ashbrook D, Kopple JD (1990) "Multicenter trial of L-carnitine in maintenance hemodialysis patients
A physical examination will be performed, and your current weight will be recorded